Phase III Trial to Cost ~CA$3.75 million with Awakn’s contribution expected to be ~CA$1.25 million Marks First Psychedelic Phase III Trial Ever to Receive Government Funding TORONTO, CANADA, 20 July,…

TORONTO, CANADA, July 15, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on…

Awakn Provides Business Update on Progressing its Lead Program from Phase II b to Phase III TORONTO, CANADA, July 05, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE:…

TORONTO, CANADA, June 20, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term…

Awakn delivered revenue growth of 24% in the quarter TORONTO, CANADA, June 14, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (‘Awakn’), a biotechnology company, researching, developing,…

Seasoned Leader Brings Deep Knowledge of US Biotech Market to Awakn TORONTO, CANADA, June 7, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing,…

Study Initiated Following Recent Successful Pilot Study and Patent Filing TORONTO, CANADA, June 2, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (‘Awakn’), a biotechnology company, researching, developing,…

Successful Behavioral Addiction Study Supplied Data for Patent TORONTO, CANADA, May 26, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and commercializing…

TORONTO, CANADA, May 24, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus…

Promising Results Merit Larger Study Which Awakn is Initiating TORONTO, CANADA, May 19, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and…

Dr. Dhandayudham Brings Significant Frontline Addiction and Mental Health Medical Leadership Experience to Awakn TORONTO, CANADA, May 17, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (‘Awakn’), a…

TORONTO, CANADA, April 28, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and delivering combined therapeutics to treat addiction,todayis reporting…